Hamilton Thorne (TSE:HTL) has released an update.
Elevate Your Investing Strategy:
- Take advantage of TipRanks Premium at 50% off! Unlock powerful investing tools, advanced data, and expert analyst insights to help you invest with confidence.
- Make smarter investment decisions with TipRanks' Smart Investor Picks, delivered to your inbox every week.
Hamilton Thorne Ltd. has reported a robust first quarter for 2024 with a 16% increase in sales to $19.4 million and a 24% rise in Adjusted EBITDA to $3.5 million, showcasing strong financial performance and adherence to their annual guidance. The company observed a significant improvement in gross profit margin to 52.4% and confirmed their full-year sales forecast, indicating a 10-15% organic growth. These results reflect a solid demand for Hamilton Thorne’s products in IVF/ART clinics and laboratories worldwide.
For further insights into TSE:HTL stock, check out TipRanks’ Stock Analysis page.